Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Calaspargase pegol (Primary) ; Dasatinib (Primary) ; Dasatinib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Folinic acid (Primary) ; Folinic acid (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Tioguanine (Primary) ; Vincristine (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Doxorubicin
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 Jun 2025 Planned number of patients changed from 680 to 222.
  • 05 Jun 2025 Status changed from not yet recruiting to recruiting.
  • 21 Feb 2025 Planned initiation date changed from 28 Feb 2025 to 29 May 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top